Abbott Laboratories (NYSE:ABT) Stock Price Target Lowered at Royal Bank Of Canada

Key Points

• Royal Bank of Canada lowered Abbott’s price target from $130 to $125 while maintaining an “outperform” rating, implying 22.37% upside from the prior close. Analysts overall remain positive, with the stock carrying a “Moderate Buy” consensus rating and an average target of $117.92.
• Abbott reported quarterly EPS of $1.42, matching consensus, while revenue increased 14.5% year over year to $13.01 billion and slightly exceeded estimates.
• Despite solid quarterly results, Abbott’s outlook faces pressure from diabetes-related pricing and weakness in some medical-device businesses. The company also plans to separate its roughly $8.5 billion Nutrition business into an independent publicly traded company by the end of 2027.

Abbott Laboratories (NYSE:ABT - Get Free Report) had its target price lowered by stock analysts at Royal Bank Of Canada from $130.00 to $125.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has an "outperform" rating on the healthcare product maker's stock. Royal Bank Of Canada's price objective would suggest a potential upside of 22.37% from the company's previous close.

ABT has been the subject of a number of other reports. Robert W. Baird raised their price objective on Abbott Laboratories from $121.00 to $123.00 and gave the company an "outperform" rating in a research report on Thursday. Citigroup boosted their target price on Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a report on Friday, July 17th. Weiss Ratings raised Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, September 18th. Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price target on the stock in a research note on Thursday, August 13th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $117.92.

Abbott Laboratories Stock Performance

NYSE:ABT traded up $1.64 during mid-day trading on Thursday, hitting $102.15. The stock had a trading volume of 2,859,598 shares, compared to its average volume of 11,290,545. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $132.02. The stock has a market cap of $176.76 billion, a price-to-earnings ratio of 33.03, a PEG ratio of 1.90 and a beta of 0.59. The company's 50 day simple moving average is $105.47 and its 200 day simple moving average is $98.28. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts' consensus estimates of $1.42. The business had revenue of $13.01 billion during the quarter, compared to analysts' expectations of $12.99 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. Abbott Laboratories's quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the company posted $1.30 earnings per share. On average, equities research analysts forecast that Abbott Laboratories will post 5.53 earnings per share for the current year.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the company. Manning & Napier Advisors LLC acquired a new position in Abbott Laboratories in the 2nd quarter valued at $31,000. Summit Securities Group LLC increased its position in Abbott Laboratories by 41.3% during the 2nd quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker's stock worth $37,000 after buying an additional 118 shares during the period. Addison Advisors LLC bought a new position in Abbott Laboratories during the 2nd quarter worth $40,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of Abbott Laboratories by 221.6% during the second quarter. E Fund Management Hong Kong Co. Ltd. now owns 476 shares of the healthcare product maker's stock worth $43,000 after buying an additional 328 shares in the last quarter. Finally, Allied Private Wealth LLC acquired a new stake in shares of Abbott Laboratories during the second quarter worth $45,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter performance was broadly solid: adjusted earnings were $1.42 per share, in line with consensus, while revenue rose 14.5% year over year to $13.01 billion, slightly exceeding estimates. Comparable sales increased 7%. Abbott reaffirmed its full-year adjusted EPS guidance. Abbott third-quarter results
• Positive Sentiment: Analysts remain constructive despite trimming some targets. Robert W. Baird raised its target to $123, while BTIG, JPMorgan and TD Cowen maintained buy-equivalent ratings with targets ranging from $118 to $125, implying meaningful upside from recent levels.
• Positive Sentiment: Abbott received European regulatory clearance for Cologuard Plus, expanding the potential market for its noninvasive colorectal-cancer screening test. Cologuard Plus European approval
• Neutral Sentiment: Abbott plans to separate its approximately $8.5 billion Nutrition business—including Ensure, Similac, Pedialyte, PediaSure and Glucerna—into an independent, publicly traded company through a tax-free distribution to shareholders by the end of 2027. Management expects the transaction to give both companies more focused growth strategies, though investors must assess execution and the future value of the separated businesses. Abbott Nutrition spinoff announcement
• Negative Sentiment: Abbott lowered its 2026 sales-growth outlook, citing diabetes-related pricing pressure and weakness in electrophysiology and other medical-device areas. That guidance reduction overshadowed the quarterly revenue performance and caused the stock to decrease after the announcement. Reuters Abbott outlook report
• Negative Sentiment: Although adjusted EPS matched the broader consensus, some services reported a modest miss against the higher Zacks estimate of $1.43. Combined with the lower sales outlook and uncertainty around the spinoff, this has increased near-term investor caution.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.